Clinical comparison of ovarian stimulation and luteal support agents in patients undergoing GnRH antagonist IVF cycles.

What Was Tested

Researchers studied Follicle Stimulating Hormone and Gonadotropin-Releasing Hormone in this randomized controlled trial publication.

Who Took Part

The study group was 173 women.

By PubMed's age tags, the people studied were teenagers, young adults and adults, women only.

Subjects included 173 women aged 18-42 years with a documented history of infertility who were undergoing IVF.

Subjects were randomized to treatment with highly purified human menopausal gonadotropin (HP-hMG) or recombinant human follicle-stimulating hormone (rhFSH) for ovarian stimulation and progesterone vaginal inserts (PVIs) or intramuscular injection of progesterone in oil (PIO) for luteal support.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Follicle Stimulating Hormone and who got the comparison, which limits bias.

Everyone knew when Follicle Stimulating Hormone was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

More than one site took part, so the women came from several places.

A phase 4, multicenter, randomized, open-label, exploratory clinical trial was performed at 7 assisted reproductive technology centers in the United States.

Protocols for IVF followed the standard practices of participating centers within the parameters of the study.

What Was Measured

PubMed files the paper under topics including Corpus Luteum Maintenance, Fertility Agents, Female, Fertilization in Vitro, Follicle Stimulating Hormone, Gonadotropin-Releasing Hormone, Infertility, Female and Menotropins.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Follicle Stimulating Hormone and Gonadotropin-Releasing Hormone in 173 women.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (The Journal of reproductive medicine), a journal based in United States.

More context: all human trials.